Target hemoglobin level for EPO therapy in CKD

American Journal of Kidney Diseases

Volumn 47, Issue 1, 2006, Pages 171-173

  Parfrey, Patrick S ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD CLOTTING DISORDER; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DRUG TARGETING; EDITORIAL; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEMATOCRIT; HEMODIALYSIS; HUMAN; MEDICAL LITERATURE; MORTALITY; QUALITY OF LIFE; RISK FACTOR; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOSIS;

ANEMIA; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; ERYTHROPOIETIN, RECOMBINANT; GOALS; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RENAL DIALYSIS; THROMBOPHILIA;

EID: 29244440847     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2005.11.001     Document Type: Editorial

References (17)

1. N. Muirhead, J. Bargman, E. Burgess Evidence-based recommendations for the clinical use of recombinant human erythropoietin Am J Kidney Dis 26 suppl 1 1995 S1 S24
2. N. Volkova, L. Arab Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients Am J Kidney Dis 47 2006 24 36
3. A.J. Collins, S. Li, W. St Peter Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39% J Am Soc Nephrol 12 2001 2465 2473
4. S. Li, A.J. Collins Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients Kidney Int 65 2004 626 633
5. R.N. Foley, P.S. Parfrey, G.M. Kent, J.D. Harnett, D.C. Murray, P.E. Barre Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease J Am Soc Nephrol 11 2000 912 916
6. R.N. Foley, P.S. Parfrey, J.D. Harnett, G.M. Kent, D.C. Murray, P.E. Barre The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease Am J Kidney Dis 28 1996 53 61
7. A. Besarab, W.K. Bolton, J.K. Browne The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 1998 584 590
8. T. Greene, J. Daugirdas, T. Depner Association of achieved dialysis dose with mortality in the hemodialysis study an example of "dose-targeting bias." J Am Soc Nephrol 16 2005 3371 3380
9. R.N. Foley, P.S. Parfrey, J. Morgan Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy Kidney Int 58 2000 1325 1335
10. P.S. Parfrey, R.N. Foley, B.H. Wittreich, D.J. Sullivan, M.J. Zagari, D. Frei Double blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic cardiac disease J Am Soc Nephrol 16 2005 2180 2189
11. M. Tonelli, W.C. Winkelmeyer, K.K. Jindal, W.F. Owen, B.J. Manns The cost effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients Kidney Int 64 2003 295 304
12. B. Leyland-Jones BEST Investigators Breast cancer trial with erythropoietin terminated unexpectedly Lancet Oncol 5 2003 206 207
13. M. Henke, R. Laszig, C. Rube Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy Randomized, double-blind, placebo-controlled trial Lancet 362 2003 1255 1260
14. D.S. Keith, G.A. Nichols, C.M. Gullion Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization Arch Intern Med 164 2004 659 663
15. J.L. Abramson, C.T. Jurkovitz, V. Vaccarino Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population The ARIC Study Kidney Int 64 2003 610 615
16. M.A. Pfeffer, S.D. Solomon, P. Ivanovich, A.K. Singh, J.J. McMurray Uncertainty in the treatment of anemia of chronic kidney disease Rev Cardiovasc Med 6 suppl 3 2005 S35 S41
17. T.C. Mix, R.M. Brenner, M.E. Cooper Rationale - Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Evolving the management of cardiovascular risk in patients with chronic kidney disease Am Heart J 149 2005 408 413